Investigational drug · Phase 3
ASC30 A1
Also called: ASC30
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Weight Management, Obesity, Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
2 still active
All registered trials
4
Any phase or sponsor naming "ASC30 A1"
First trial start
2024
Sep 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASC30 A1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Weight Management
- Obesity
- Overweight
- Type 2 Diabetes Mellitus
- T2DM (Type 2 Diabetes Mellitus)
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ASC30 A1" as an intervention, largest first.
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesPivotal-lookingRecruiting
Ascletis Pharma (China) Co., LimitedIndustry
NCT07743463 · 3,003 participants (planned) · Start Aug 31, 2026 · Primary completion Jul 2028
Drug: ASC30 tablets A1; Placebo · For: Obesity; Overweight; Chronic Weight Management
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 122 sites in all
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesPivotal-lookingRecruiting
Ascletis Pharma (China) Co., LimitedIndustry
NCT07743450 · 1,560 participants (planned) · Start Aug 28, 2026 · Primary completion Jul 2028
Drug: ASC30 tablets A1; Placebo · For: Obesity; Overweight; Chronic Weight Management and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Peoria, Arizona · 135 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related ComorbiditiesPivotal-lookingCompleted
Ascletis Pharma (China) Co., LimitedIndustry
NCT07002905 · 125 participants · Start Jul 3, 2025 · Primary completion Dec 8, 2025
Drug: ASC30 tablets or ASC30 tablets A1 or placebo · For: Chronic Weight Management
Sites: Rogers, Arkansas; Fort Myers, Florida; Miami, Florida · 6 sites in all
Ascletis Pharma (China) Co., LimitedIndustry
NCT06680440 · 72 participants · Start Aug 26, 2024 · Primary completion Apr 3, 2025
Drug: ASC30 · For: Weight Management
Sites: Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of antimicrobial activities of sequential spray applications of decontamination treatments on chicken carcasses.
Benli H, Sanchez-Plata MX, Ilhak OI, et al. · Asian-Australas J Anim Sci 2015
Also in development for Chronic Weight Management
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- AleniglipronPhase 36 trials
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.